Last reviewed · How we verify
concomitant temozolomide (TMZ)
Temozolomide is an alkylating agent that works by interfering with DNA replication in cancer cells.
Temozolomide is an alkylating agent that works by interfering with DNA replication in cancer cells. Used for Glioblastoma multiforme, Anaplastic astrocytoma.
At a glance
| Generic name | concomitant temozolomide (TMZ) |
|---|---|
| Sponsor | Alliance for Clinical Trials in Oncology |
| Drug class | alkylating agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Temozolomide is a prodrug that is converted into its active form, MTIC, which then methylates DNA, leading to DNA damage and cell death. This mechanism is particularly effective in rapidly dividing cells, such as cancer cells.
Approved indications
- Glioblastoma multiforme
- Anaplastic astrocytoma
Common side effects
- Myelosuppression
- Nausea and vomiting
- Fatigue
- Headache
- Dizziness
Key clinical trials
- DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) (PHASE2)
- Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma (PHASE2)
- Treatment Intensification With Temozolomide in Adults With a Glioblastoma (PHASE3)
- A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. (PHASE1)
- Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma (PHASE2, PHASE3)
- A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma (PHASE1, PHASE2)
- Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) (PHASE2)
- Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |